Immune checkpoint pathways such as PD-1/PD-L1 and CTLA-4 are promising new immunotherapy targets for the treatment of cancer and autoimmunity. Immune checkpoint reporter-based bioassays provide a simple, consistent, and reliable cell-based assay to measure Ab function throughout the drug development pipeline.
The brief chalk talk below describes the assay principals of the reporter-based bioassay that monitors the functional blockade of PD-1/PD-L1 interactions.
Latest posts by Kelly Grooms (see all)
- Lessons in History, Hope and Living with Lynch Syndrome from the “Daughter of Family G” - August 26, 2020
- Improving SARS-CoV-2 Antibody Detection with Bioluminescence - August 11, 2020
- Promega Leverages Long-Time Experience in MSI Detection with European Launch of CE-Marked IVD Assay for Microsatellite Instability - June 10, 2020